Perspective Therapeutics (CATX) Net Income towards Common Stockholders (2010 - 2026)

Perspective Therapeutics has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$26.8 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 24.67% year-over-year to -$26.8 million; the TTM figure through Jun 2026 stood at -$119.8 million (down 22.21% YoY), while the FY2025 annual figure was -$103.9 million, down 26.22% from the prior year.
• Net Income towards Common Stockholders came in at -$26.8 million for Q2 2026 at Perspective Therapeutics, up from -$28.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.3 million in Q1 2022 to a low of -$43.2 million in Q4 2024.
• Average Net Income towards Common Stockholders over 5 years is -$17.2 million, with a median of -$13.9 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders slumped 568.7% in 2024 and gained 11.41% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$8.5 million in 2022, then sank by 171.57% to -$23.2 million in 2023, then plunged by 86.18% to -$43.2 million in 2024, then grew by 11.41% to -$38.3 million in 2025, then surged by 30.03% to -$26.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$26.8 million in Q2 2026, -$28.7 million in Q1 2026, and -$38.3 million in Q4 2025.